Jemperli was the first drug in the class to be approved for front-line use in endometrial cancer last year, based on progression-free survival data from RUBY, but with a restricted label that ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or ...